Moreover, there are additional factors buttressing a need for caution: Two retrospective analyses of Medicare claims both found increased risks of stroke and death among patients using Avastin for wet AMD over Lucentis.
FORBES: Blinded By Savings? Is Cost Trumping Risk On Blindness Drug?